Booth Bruce's Form 4 filing
Kymera Therapeutics, Inc. (KYMR) · filed Jul 9, 2024
- Accession no.
- 0001415889-24-019440
- Filed
- Jul 9, 2024
- Trade date
- Jul 9, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 10 non-derivative transactions. Open-market sales total $17.3M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Booth BruceCIK 0001451612 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 9, 2024 | Common Stock | SSaleDisposed | −24,449 | $35.57F2 | −$869,650.93 | 4,523,951 | Indirect | |
| Jul 9, 2024 | Common Stock | SSaleDisposed | −28,718 | $36.40F4 | −$1,045,335.2 | 4,495,233 | Indirect | |
| Jul 9, 2024 | Common Stock | SSaleDisposed | −41,763 | $37.41F5 | −$1,562,353.83 | 4,453,470 | Indirect | |
| Jul 9, 2024 | Common Stock | SSaleDisposed | −183,868 | $38.48F6 | −$7,075,240.64 | 4,269,602 | Indirect | |
| Jul 9, 2024 | Common Stock | SSaleDisposed | −96,386 | $39.26F7 | −$3,784,114.36 | 4,173,216 | Indirect | |
| Jul 9, 2024 | Common Stock | SSaleDisposed | −5,133 | $35.57F2 | −$182,580.81 | 796,889 | Indirect | |
| Jul 9, 2024 | Common Stock | SSaleDisposed | −6,030 | $36.40F4 | −$219,492 | 790,859 | Indirect | |
| Jul 9, 2024 | Common Stock | SSaleDisposed | −8,769 | $37.41F5 | −$328,048.29 | 782,090 | Indirect | |
| Jul 9, 2024 | Common Stock | SSaleDisposed | −38,606 | $38.48F6 | −$1,485,558.88 | 743,484 | Indirect | |
| Jul 9, 2024 | Common Stock | SSaleDisposed | −20,238 | $39.26F7 | −$794,543.88 | 723,246 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.96 to $35.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (4), (5), (6) and (7).
Referenced by the price of 2 transactions in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.91 inclusive.
Referenced by the price of 2 transactions in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.96 inclusive.
Referenced by the price of 2 transactions in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.97 to $38.96 inclusive.
Referenced by the price of 2 transactions in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.97 to $39.85 inclusive.
Referenced by the price of 2 transactions in Table I.